AAP News Vol. 14 No. 10 October 1998, p. 10
© 1998 American Academy of Pediatrics
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

 Previous Article  |  Next Article 

Palivizumab granted licensure for prophylaxis of RSV disease

Licensure of palivizumab (SynagisTM(MEDI-493)) for prophylaxis of respiratory syncytial virus (RSV) disease was granted June 19 by the U.S. Food and Drug Administration. Palivizumab is an intra-muscularly administered monoclonal antibody preparation.

The approval of palivizumab was based on a large, randomized study demonstrating a 55 percent reduction in the risk of hospitalization due to RSV infections in high-risk infants and toddlers. Both palivizumab and respiratory syncytial virus immune globulin intravenous (RSV-IGIV) are available for protecting high-risk infants and toddlers against serious complications from RSV infections. RSV-IGIV is contraindicated and palivizumab is not recommended for children with cyanotic congenital heart disease.